Komori
Share Issuance and Disposal4582SymBio Pharmaceuticals LimitedPharmaceuticals

Notice of Completion of the Acquisition and Cancellation of the 58th, 66th and 67th Stock Acquisition Rights and of Payment of the Issue Price for the 70th and 71st Stock Acquisition Rights Issued Through Third-Party Allotment

Payment of the ¥2,880,000 issue price for the No. 70 and No. 71 Stock Acquisition Rights was completed, and the allotment became effective. In addition, all remaining No. 58, No. 66 and No. 67 Stock Acquisition Rights were acquired and cancelled.

Worth reading
65In focus
Scored from 3 of 5 sections
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
96000000
Number of potential shares
Wording
Avoiding a definitive answer
How definitive the wording is.

Details of issuance or disposal

Issuance of stock acquisition rights with an exercise price adjustment clause through a third-party allotment (No. 70 and No. 71) and acquisition and cancellation of existing stock acquisition rights

Who receives how much

No. 70 Stock Acquisition Rights: equivalent to 48,000,000 shares; No. 71 Stock Acquisition Rights: equivalent to 48,000,000 shares (960,000 stock acquisition rights in total, with 100 shares per right)

EVO FUND: 480,000 No. 70 Stock Acquisition Rights and 480,000 No. 71 Stock Acquisition Rights

The lower thin line represents the existing number of shares to which these shares will be added.

No. 70 Stock Acquisition Rights: ¥4 per right; No. 71 Stock Acquisition Rights: ¥2 per right
Total issue value

¥2,880,000

Amount of funds to be raised
¥6,768,880,000 (after combining the total payment amount and the contribution amount upon exercise of the stock acquisition rights, and deducting issuance expenses)
Terms of the stock acquisition rights
Exercise price
Initial exercise price: ¥71. Subject to an adjustment clause. Adjusted to 100% of the closing price on the price calculation date, with a lower exercise price of ¥36. No upper exercise price.
Exercise period
From 3 September 2026 to 3 September 2029
Number of Stock Acquisition Rights
960,000 stock acquisition rights issued in total (480,000 No. 70 and 480,000 No. 71). Unexercised balance: Not disclosed
Intended allottee's holding policy
Any transfer of these stock acquisition rights requires approval by resolution of the Company's Board of Directors. Other details of the holding policy are Not disclosed.
Payment date
2 September 2026
Most recent equity financing
1 June 2022: No. 58 Stock Acquisition Rights issued through a third-party allotment; 12 August 2025: No. 66 and No. 67 Stock Acquisition Rights issued through a third-party allotment
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of stock acquisition rights with an exercise price adjustment clause through a third-party allotment (No. 70 and No. 71) and acquisition and cancellation of existing stock acquisition rights
Number of shares to be issued or disposed ofNo. 70 Stock Acquisition Rights: equivalent to 48,000,000 shares; No. 71 Stock Acquisition Rights: equivalent to 48,000,000 shares (960,000 stock acquisition rights in total, with 100 shares per right)
Issue price and disposal priceNo. 70 Stock Acquisition Rights: ¥4 per right; No. 71 Stock Acquisition Rights: ¥2 per right
Total issue value¥2,880,000
Amount of funds to be raised¥6,768,880,000 (after combining the total payment amount and the contribution amount upon exercise of the stock acquisition rights, and deducting issuance expenses)
Payment date2 September 2026
Intended allotteeEVO FUND: 480,000 No. 70 Stock Acquisition Rights and 480,000 No. 71 Stock Acquisition Rights
Intended allottee's holding policyAny transfer of these stock acquisition rights requires approval by resolution of the Company's Board of Directors. Other details of the holding policy are Not disclosed.
Exercise priceInitial exercise price: ¥71. Subject to an adjustment clause. Adjusted to 100% of the closing price on the price calculation date, with a lower exercise price of ¥36. No upper exercise price.
Exercise periodFrom 3 September 2026 to 3 September 2029
Number of Stock Acquisition Rights960,000 stock acquisition rights issued in total (480,000 No. 70 and 480,000 No. 71). Unexercised balance: Not disclosed
Most recent equity financing1 June 2022: No. 58 Stock Acquisition Rights issued through a third-party allotment; 12 August 2025: No. 66 and No. 67 Stock Acquisition Rights issued through a third-party allotment
Items this document does not state (16)
Estimated issuance expensesSpecific use of fundsDilution RateTotal number of issued sharesBasis for determining the amount to be paidTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

For the No. 70 and No. 71 Stock Acquisition Rights, payment of the issue price based on a resolution of the Board of Directors dated 17 August 2026 was completed. For the No. 58, No. 66 and No. 67 Stock Acquisition Rights, the Company resolved to acquire and cancel them. This document does not state any other reasons for the acquisition, cancellation or issuance.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Completion of the Acquisition and Cancellation of the 58th, 66th and 67th Stock Acquisition Rights and of Payment of the Issue Price for the 70th and 71st Stock Acquisition Rights Issued Through Third-Party Allotment | SymBio Pharmaceuticals Limited (4582) timely disclosure | Komori